LABCORP HOLDINGS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 197.3 USD | -1.17% |
|
-4.15% | -13.41% |
| May. 23 | Some of the biggest splits in Corporate America | RE |
| May. 16 | Declaration of Voting Results by Laboratory Corporation of America Holdings | CI |
ETFs positioned on Labcorp Holdings Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.97% | 2 M€ | 0.00% | ||
| 1.95% | 8 M€ | +4.90% | ||
| 0.82% | 17 M€ | +7.83% | - | |
| 0.43% | 9 M€ | +10.21% | ||
| 0.39% | 92 M€ | +0.06% | - | |
| 0.27% | 9 M€ | -.--% | - | |
| 0.23% | 1 M€ | +11.94% | - | |
| 0.23% | 13 M€ | -.--% | - | |
| 0.23% | 3 M€ | +7.32% | - | |
| 0.19% | 5 M€ | -72.95% | - | |
| 0.19% | 50 M€ | +11.25% | ||
| 0.18% | 2 M€ | +20.44% | - | |
| 0.15% | 7 M€ | +5.52% | - | |
| 0.15% | 32 M€ | +0.61% | - | |
| 0.15% | 17 M€ | +5.84% | - | |
| 0.14% | 469 M€ | -2.05% | ||
| 0.14% | 3,859 M€ | +18.82% | - | |
| 0.12% | 2,383 M€ | +14.36% | ||
| 0.11% | 4,592 M€ | +11.18% | ||
| 0.11% | 1,006 M€ | -.--% | - | |
| 0.11% | 414 M€ | +13.26% | - | |
| 0.11% | 322 M€ | +13.88% | - | |
| 0.11% | 29 M€ | -.--% | - | |
| 0.10% | 219 M€ | +17.17% | - | |
| 0.10% | 1,448 M€ | -.--% | - | |
| 0.10% | 8 M€ | +7.15% | - | |
| 0.10% | 744 M€ | +9.67% | ||
| 0.09% | 330 M€ | -.--% |
Labcorp Holdings Inc. provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company serves clients in more than 100 countries.
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
199.6
USD
Average target price
239.7
USD
Spread / Average Target
+20.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.41% | 16.83B | |
| +16.79% | 83.47B | |
| -31.63% | 69.72B | |
| -3.24% | 26.37B | |
| +4.13% | 17.86B | |
| +0.77% | 15.7B | |
| +73.38% | 13.45B | |
| +72.07% | 12.81B | |
| -3.13% | 12.44B | |
| +3.58% | 12.35B |
- Stock Market
- Equities
- LH Stock
- Funds and ETFs Labcorp Holdings Inc.
